IFP @kroetscha explains China's "Dare To Be Second" strategy for beating American biotech without inventing first: "It's not necessarily that first innovator or that first brand new molecule that targets a new biological pathway that winds up winning in the race to becoming the best selling drug. Often it is that fast follower, the second one that is better engineered. We certainly see that in GLP-1s where we see the more recent medications having greater commercial success than the original…